PPARγ Activation: A Potential Treatment For Pulmonary Hypertension
Georg Hansmann, Roham T. Zamanian · Science Translational Medicine · 2009
The pathobiology of pulmonary arterial hypertension (PAH) involves multiple molecular pathways and environmental modifiers and is characterized by progressive obliteration of pulmonary arterioles, leading to increased pulmonary vascular resistance (PVR), right heart failure, and death in approximately 40 to 60% of patients 5 years after diagnosis. There is emerging evidence that many key genes involved in PAH development are targets of the insulin-sensitizing transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma), and that pharmacological PPARgamma activation would lead to their beneficial induction or repression and subsequent antiproliferative, anti-inflammatory, proapoptotic, and direct vasodilatory effects in the vasculature. PPARgamma acts downstream of bone morphogenetic protein receptor II (BMP-RII), which is the cell surface receptor that is mutated or dysfunctional in many forms of PAH. Because our recent clinical observations indicate that insulin resistance may be an environmental risk factor or disease modifier ("second hit"), we suggest that PPARgamma-activating agents might be beneficial in the future treatment of both insulin-resistant and insulin-sensitive PAH patients with or without BMP-RII mutations.
Cited by 76 works. doi:10.1126/scitranslmed.3000267
Authors
References
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
- Updated Clinical Classification of Pulmonary Hypertension
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
- Updated Clinical Classification of Pulmonary Hypertension
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ
- A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
- Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
- Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.